Novel Tricyclic KRAS Inhibitors for the Treatment of Cancer.
Journal: ACS Medicinal Chemistry Letters
Published:
Abstract
The invention described in this patent application relates to oral compounds represented by Formula I. These compounds are designed to specifically target and inhibit KRAS alleles, providing both therapeutic and prophylactic potential in mammals, particularly for the treatment of KRAS-driven cancers.
Authors
Taoqian Zhao, Steven Liang